Blog

Fadi Haddad: Happy to present data on the role of inotuzumab in patients with B-ALL at ASH24

Fadi Haddad/X

Dec 12, 2024, 14:22

Fadi Haddad: Happy to present data on the role of inotuzumab in patients with B-ALL at ASH24

Fadi Haddad, Assistant Professor in the Department of Leukemia at the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Happy to present data from MD Anderson Cancer Center on the role of inotuzumab in eradicating MRD in patients with B-ALL at ASH24:-

N=30
67% response rate, MRD conversion
3-year OS 56%
Low grade AEs, but 2 SOS (both in patients with ponatinib, Gr 5=1).”

Fadi Haddad is an Assistant Professor in the Department of Leukemia at the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, TX. He serves as a member of the Leading Clinical Research Faculty Learning Series. His postgraduate training includes a clinical fellowship in leukemia at MD Anderson Cancer Center and a clinical residency in hematology/oncology at Hotel Dieu de France Hospital in Beirut.

ASH24 cancer Cancer Medicine Fadi Haddad fight against cancer Global fight against cancer Happy Inotuzumab Leukemia MD Anderson Cancer Center MRD OncoDaily Oncology University of Texas

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer